How pharma giant Gilead turns public money into private profit
The American taxpayer has paid handsomely to develop a drug called Remdesivir which media reports say could become a major player in the fight against the coronavirus. Remdesivir was developed by the pharmaceutical company Gilead Sciences with tens of millions of dollars from three federal agencies, but it was a failure among anti-virals. Well, now it shows promise, as well as profitability. And Gilead is keeping that money and not refunding taxpayers. Annette Gaudino, State & Local Policy Director at the Treatment Action Group, joins the show with John.